Value proposition

XING Technologies has a clear vision in applying diagnostic nanotechnologies to globally enhance healthcare systems.

We are an Australian-owned and operated cancer pathology lab that uses genetic sequencing to inform doctors and patients about precision cancer treatment options.

Precision medicine offers cancer patients therapy options that are targeted specifically to their cancer. XING Genomic Services offers a range of cancer genetic tests for both newly diagnosed cancer patients and patients dealing with a recurrence of their disease.

The results analysed in our lab will determine whether the genetic alterations found in your cancer match genetic changes that are associated with known therapies that may have not been previously considered by your treating doctor. Performing genetic testing is a powerful diagnostic tool that may also give you clarification of your cancer type.

All clinically relevant genetic alterations and possible clinical trials will be reported in a clear and easy to read personalised XING Genomic Services report. The information surrounding your results will facilitate a discussion between you and your medical team.

HRD Test
This is a multi-gene test that analyses 18 genes involved in homologous recombination repair deficiency (HRD) and 8 genes that are diagnostically significant. This test is aimed at breast, ovarian, prostate, and pancreatic cancers.

In addition, epigenetic causes of HRD can be interrogated by testing the BRCA1 and RAD51C gene promoters.

STP Test
This is a multi-gene test that analyses hotspot alterations considered to be driving mutations in solid tumours. It includes hotspots in 47 genes involved in colorectal, melanoma, thyroid, non-small cell lung, and pancreatic cancers, as well as gastro-intestinal stromal tumours (GIST) and gliomas.

Oncology, Haematology, Nanotechnology, Personalised Medicine, Metastatic, Cancer Clinical Trials, Targeted therapy, Next generation screening, Breast Cancer, Prostate Cancer, Recurrence, Directed Therapies , Cancer, Ovarian Cancer, Chemotherapy, Genomic testing, BRCA, PARP, Metastatic, IHaveCancer, and CDK4/6 Inhibitors